The combination of Abgenix Inc.'s XenoMouse technology to generate human antibodies with Human Genome Sciences Inc.'s secreted protein target antigens illustrates the potential for exploiting genomics with a rapid product development cycle.
HGSI (Rockville, Md.) has identified and characterized thousands of secreted proteins, many of which may be useful drug targets (see BioCentury, Nov. 8). ABGX (Fremont, Calif.) will use its XenoMouse technology to generate human antibodies against these target antigens.
"By making our technology available to them and their technology available to us, we're exchanging free options," said R. Scott Greer, ABGX's